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SOCIOECONOMIC FACTORS’ EFFECT ON THE MAINTENANCE OF 
ASTHMA: A CHRONIC PULMONARY DISEASE 
ANGELEQUE S. HARTT 
 
ABSTRACT 
 
 Asthma is a chronic lung inflammatory disease that causes inflammation and 
narrowing of the airways. Swelling of the airways can be caused by the activation of 
cytokines that lead to an inflammatory or allergenic-like response. Environmental factors, 
both indoors and outdoors, have been found to increase the likelihood of asthma in 
children. Among those found to impact disease are air pollutants such as ozone, nitric 
dioxide, and particulate matter, as well as home exposures, like cockroaches and rodents. 
Those who have multiple or increased exposure to these pollutants are more likely to 
experience exacerbated symptoms and uncontrolled asthma. There currently is no cure 
for asthma, but effective therapies have been found to treat the symptoms associated with 
asthmatic episodes. During an asthma attack, due to narrowing of the airways, individuals 
experience wheezing, chest tightness, and even shortness of breath. To combat these 
occurrences, physicians use inhaled corticosteroids (ICS), Beta-agonist, or a combination 
of both to relieve symptoms. 
 
 In the United States asthma affects 25.8 million people. This number is projected 
to increase as the US continuously becomes more industrialized and as environmental 
conditions deteriorate. Research conducted by the Center for Disease Control concluded 
 vi 
that the prevalence of asthma increased amongst the general population, however, once 
the data were disaggregated by race, age, gender, and SES significant increases were noted 
amongst some groups but not others. Most notably, on average, children, women, Puerto 
Ricans, and people living in poverty as defined by federal guidelines had the highest 
asthma prevalence. 
 
 Chronic diseases like asthma also produce substantial burdens on the healthcare 
system. Asthmatics on average require three-times as many prescriptions, twice as many 
emergency room visits and four-times as many hospitalizations as individuals without 
asthma in the same demographic population.9 Additionally, when an expenditure analysis 
was carried out, it revealed that children with asthma cost approximately three-times 
more per capita per child than adolescents without asthma.9 Chronic disease occurs over 
the duration of individual lives. Thus, poorly managed, they will cause preventable 
increases in disability-adjusted-life years, premature death, and health care expenditure 
for both the individual and the broader healthcare system. The observed increases will 
predominantly impact the indicated high-risk populations. 
 
 The prevalence of asthma in urban settings was anticipated by researchers based 
on known environmental influences. However, the discovery of a higher prevalence and 
mortality rate of asthma within impoverished communities, in comparison to other urban 
communities, is not yet fully understood. Through this research an association between 
high-risk populations with uncontrolled asthma and a lack of patient education, low 
 vii 
socioeconomic status, and utilization of Medicaid insurance was found, which indicates 
the influence of these factors on asthma control. Improving current asthma interventions 
by remodeling them to take a broader stance on asthma prevention, treatment and 
maintenance and through acknowledgement of the impact disparities, asthma will likely 
be better controlled for all individuals in the Unites States.   
 viii 
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INTRODUCTION 
 Asthma is a chronic lung disease that causes inflammation and narrowing of the 
airways1. An asthmatic episode is characterized by one or a combination of wheezing, 
chest tightness, shortness of breath, and coughing2. Inflammation of the airways can be 
caused by the activation of cytokines that lead to an inflammatory or allergenic-like 
response. The specific type of cytokines activated is dependent on the type of mediator 
that binds3. In a normal functioning lung, there are defense barriers in place to prevent 
pathogens and foreign particles from permeating the lining of the respiratory tract or 
entering the alveoli. However, in asthmatic patients, these mechanisms are usually 
defective3. Both environmental and genetic factors have been correlated with asthma, yet 
environmental factors have been more extensively researched and agreed upon by the 
literature. The high prevalence of asthma discovered in urban settings was anticipated by 
researchers based on known environmental influences4. However, the discovery of higher 
prevalence and mortality of asthma in communities of low social economic status in 
comparison to other urban area communities, is not yet fully understood4.  
 
Anatomy of the Lungs and Intrinsic Defense Mechanism 
The lungs are a pair of organs that sit in the thoracic cavity and surround the 
heart. Each lung is covered by a double-layered pleura that supports its primary role of 
gas exchange5. The lungs are connected to the nasal and oral cavity, in which gas enters 
the body via the trachea and bronchi. The characteristics of the latter structures provide 
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initial protection to the respiratory system. The nasal cavity, composed of a mucous 
membrane and cilia, moisten, filters, and warms inhaled air. Under normal conditions, 
bacteria, dirt, and chemical particle of significant size that enter the cavity are entrapped 
in the mucus, whereas those that manage to bypass this defense, are directed towards the 
back of the throat in hopes of being killed by the digestive system5. The trachea and 
bronchi are divided into conducting and respiratory zones, where the conducting zone 
provides another key defense known as the mucociliary escalator. This mechanism 
utilizes the action of cilia located in the respiratory epithelium to push dust and particles 
towards the oral cavity to be expelled5. Defects in these two mechanisms are commonly 
found in individuals diagnosed with asthma.  
 
Environmental Factors Associated with Asthma 
Environmental factors, both indoors and outdoors, have been found to increase 
the likelihood of asthma in children. Among those found include air pollutants ozone, 
nitric dioxide, and particulate matter, as well as home exposures, like cockroaches and 
rodents6. These factors have been shown to elicit an asthmatic episode by triggering the 
production of reactive cytokines, weakening the respiratory defense barriers, or a 
combination of both3.  
 
Outdoors, ozone is the main component in “summer smog” present in many 
cities3. It is generated by photochemical reactions involving ultraviolet radiation on 
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atmospheric mixtures3. Inhaled ozone, as well as NO2, has been found to cause 
deterioration of lung function via the breakdown of the mucociliary escalator and 
increased airway reactivity towards specific and non-specific antigens6. Ozone also 
causes an increase in the release of inflammatory agents that trigger bronchoconstriction. 
Nitric dioxide is also found in air pollution and can lead to the formation of ozone. 
However, the most abundant concentrations of NO2 are found indoors due to the use of 
gas stoves and space heaters3. Lastly, particulate matter is considered to be the most 
serious pollutant, as it has been linked to many diseases which impact health3. PM is a 
mixture of solid and liquid particles that differ in size and composition, which has a 
unique mechanism of causing asthma, as it does not directly cause the weakening of 
defense mechanisms. Due to the variations in its composition, PM can evade defense 
mechanisms and penetrate the airways to induce airway inflammation6.  
 
Indoors, the presence of specific organisms has been linked to the exacerbation of 
asthma symptoms. Cockroaches and rodents are recognized as factors that cause asthma 
as asthmatics were found to be highly sensitized to their allergens.6 Specifically, it was 
found that the prevalence of infestations with these organisms were found to be higher in 
low socioeconomic areas in urban settings6. One or a combination of these factors have 
shown to increase asthma related symptoms and severity3. The Urban Environment and 
Childhood Asthma (URECA) study was an observational prospective analysis of the 
association between the development childhood asthma and urban inner-city 
environments conducted in Baltimore, Boston, New York City and St. Louis.7 This study 
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followed a total of 609 newborns (560 newborns from families with a high risk of asthma 
and 49 newborns from asymptomatic families) from birth until 7 years of age to assess 
for any abnormal respiratory development. 7 This study, which was comprised primarily 
of African-American and Hispanic women of low socioeconomic status, showed a 
recurrent wheeze at 3 years of age and the development of asthma by the age of 7.7 
 
Asthma Burden on the US Healthcare System  
 In 1989 the Global Initiative for Asthma (GINA) program was started to raise 
awareness around the increase in prevalence of asthma.8 Currently, in the United States 
this chronic ailment affects 25.8 million people and is projected to continuously increase 
as this and extended nations become more urbanized. However, since this prevalence was 
calculated based on conservative criteria, the true value is expected to be significantly 
higher.9 The Center for Disease Control (CDC) conducted a report to assess the 
prevalence, health resources used and mortality rate associated asthma in the US between 
2001 and 2010. Through this analytical time period, the prevalence of asthma increased 
steadily amongst the general population, however, once the data was stratified for race, 
age, gender, and SES substantial increases were noted amongst distinct groups. Most 
notably, on average, children, females, Puerto Ricans, and low socioeconomic 
communities were found to have the highest prevalence of asthma (Figure 1).9 These 
characteristics are not unique to the US as the trend of chronic illnesses continues to 
disproportionately affect those living in poverty around the world.8  
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Lastly, it was found that although the prevalence rate of asthma continued to 
climb during the study period, the overall mortality rate of the population steadily 
declined, while hospitalizations, ED visits and outpatient visits in relation to asthma 
remained steady. This indicates that currently available treatments were effective at 
subsiding the acute symptoms of an asthmatic episode but not managing the disease 
burden on the population (Figure 2). 
 
Figure 1. Prevalence of asthma based on age, sex, race, and SES within the 
US9 
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Figure 2. Health care encounters per 100 persons with Asthma and Asthma 
related deaths per 1,000 persons.9 
 
 
A comparative study conducted by Lozano et. al analyzing the per capita cost of 
adolescent medical care for asthmatic and non-asthmatic individuals in the US was used 
to depict the burden of asthma on the US healthcare system. As indicated in the findings 
of this study, adolescents with asthma required three times as many prescriptions, twice 
as many emergency department (ED) visits and four times as many hospitalizations as 
individuals without asthma in the same demographic population.9 Additionally, when 
asthma care alone was compared to that of all medical care for non-asthmatic children, 
the utilization rates were equal (Table 1). Furthermore, when a cost analysis was carried 
out, it revealed that children with asthma cost approximately three times more per capita 
per child than adolescents without asthma9 (Figure 3). Collectively, as indicated by this 
study, chronic diseases like asthma place a substantial resource and economic burden on 
the US healthcare system.
  
 
 
 
 
 
Table 1. Comparison of healthcare utilization by US children with and without asthma9 
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Figure 3. Health care expenditure per child per year for children with and without asthma in the US.
8 
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Asthma Treatments 
There is no cure for asthma, however many effective treatments oriented at 
symptom management, have been discovered. As previously discussed, when an 
asthmatic episode is triggered, bronchi inflammation occurs, and leads to the constriction 
of airways. The types of current treatments targeted at reducing inflammation are 
categorized into two categories - quick relief and long lasting medications. Although 
therapies that fall into either category can be used on their own, the current recommended 
treatment is that of combination therapy10. These include inhaled corticosteroids (ICS), 
which are considered to be the most effective, Short acting !-agonists (SABAs), long 
acting !-agonists (LABAs), and Leukotriene receptor antagonists10 (Figure 4). 
 
Figure 4. Average Physician satisfaction with currently available Asthma 
Treatments; 1= least satisfied, 10= most satisfied10 
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Although combination therapy of ICS and LABA is considered to be the most 
effective, its utilization presents with poor adherence and suboptimal therapeutic 
outcomes. A major cause of these observations is thought to be noncompliance with 
treatment10. As shown in Figure 5, the primary reason patients gave up or switched 
medications was “Symptoms went away or lessened” and the third being “medication 
was too expensive”.10  
 
Figure 5. Factors associated treatment noncompliance10. 
 
As indicated previously, the prevalence of asthma is higher in urban settings, 
more specifically in low socioeconomic communities despite the availability of effective 
treatments. Specific socioeconomic factors, other than increased environmental hazards, 
have not been adequately explained to account for this trend.  
Physicians and patients differed in their perception of
how well patients recognize ICS-related sid effects. Only
1% of patients interviewed said that they had experienced
adrenal (cortisol) suppression, 8% said they had experienced
l ng-term side effects, and 36% report d having short-term
side effects (Q18a). In contrast, 17% of physicians reported
that their patients had decreased cortisol production, 48%
said their patients had long-term side effects, and 92% said
their patients experienced short-term side effects (Q16b).
Patients stated that side effects resulting from asthma medi-
cation caused them to consider switching (29%) or to switch
medication (24%), consider skipping (26%) or skip doses
(19%), or consider stopping (21%) or stop taking the medi-
cation entirely (22%), or change dosage (26%) (Q19a).
Causes and Effects for Noncompliance
Perceptions of compliance differed between patients
and physicians. When queried regarding the percentage of
time they took their asthma medication according to their
doctor or healthcare professional instructions, 35% of pa-
tients said they were fully compliant, 32% said they were
compliant more than 50% of the time, and only 8% of
patients said they were never compliant (Q20a). However,
none of the physicians reported that their patients were fully
compliant, 54% said that their patients were at least 50%
compliant, and 5% said their patients were never compliant
(Q17b). There are multiple reasons patients reported for
being noncompliant; the most frequent responses were that
symp o s went away, they felt they didn’t eed the medica-
tion that often, or they forgot to take the medication (Table 5;
Q21a). These were also the most important reasons that
physicians reported for lack of compliance by patients, but
physicians also included lack of insurance coverage or med-
ication expense (Table 5; Q18b). Reasons that physicians
reported for knowing if their patients were complying with
treatment regimen were: asking the patients (97%), knowing
if their symptoms are controlled (89%), being told by the
patient (88%), or they weighed the inhaler (5%) (Q19b).
Physicians and patients differed in their perspectives of
the consequences of non or partial adherence to treatment
regimens. For example, 69% and 58% of patients reported
increased symptoms and limited physical activity, respec-
tively (Table 6; Q22a) as the primary consequence of none or
partial adherence to treatment. Conversely, between 90%
and 100% of physicians believed that their patients who
were not 100% compliant experienced increased symp-
toms and limited physical activity (Table 6; Q20b). For
each category, a higher percentage of physicians versus
patients believed non or partial adherence had a detrimen-
tal effect, particularly regarding the frequency and severity
of exacerbations, frequency of rescue medication use,
nighttime awakenings, and increased physician visits and
hospitalizations (Table 6).
FIGURE 2. Reasons for patients switching asthma medications. Question: Since being diagnosed with asthma, have you ever
switched from one asthma medication to another or discontinued an asthma medication because . . . .?
WAO Journal • December 2 09 US Results From the Global GAPP Survey
© 2009 World Allergy Organization 307
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Standardized Methods of Asthma Control in the US  
 The US health system, like many other health systems in the world, is 
predominately comprised of vertical programs that are geared towards the prevention and 
treatment of a pathological disease without consideration for comorbidities that 
contribute to the diseased state. With use of the aforementioned medical treatments, a 
routine procedure implemented and followed by physicians focuses on subsiding the 
presenting symptoms associated with an asthmatic episode.11 According to Higgins et. al, 
the conventional management of acute asthma is to relieve bronchospasms, improve gas 
exchange through opening of the airways, and treat the underlying cause.11  
 
Although decades of research have led to the development an effective procedure 
for when patients are experiencing acute symptoms, patient education and asthma action 
plans to prevent future attacks were often not included. This finding is significant as it 
further supports the need for horizontal programs which target not only the pathology of 
disease but also additional factors associated with the ailment. By taking a broader 
approach towards prevention, treatment and management of chronic diseases it can be 
expected to observe a decrease in prevalence across all demographics in the population. 
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SPECIFIC AIMS AND OBJECTIVES 
 
The specific aim of this literature based thesis is to assess the multiple 
socioeconomic factors on the control of asthma symptoms. As shown in the literature, 
extensive research has been done on environmental factors associated with the prevalence 
of asthma, including those associated with communities of low socioeconomic status. 
However, disparities in relation to medical insurance, socioeconomic status, and patient 
education within these specific communities also may play a role in the prevalence and 
lack of control of asthma. Assessing the causes for the lack of reduction in chronic 
diseases, such as asthma, within communities of low socioeconomic status is essential 
since these illnesses account for approximately 60% of deaths worldwide and 
disproportionately affect these communities.12 This topic is of interest, specifically 
because although it focuses on inner cities within the US, the disparities highlighted and 
potential solutions discussed can be applied to similar regions around the world. 
 
Asthma as a chronic condition and its associated medical treatment is not a new 
phenomenon within the field of health as the first case documented case of asthma 
occurred in 460-357 BC by Hippocrates.13 Despite an abundance of research surrounding 
asthma, its biological and environmental causes, as well as its increase in prevalence 
within inner city neighborhoods, the potential impact of social and economic 
disadvantages on the high burden of disease has traditionally been overlooked. 
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Uncontrolled asthma results in a higher use of health benefits and an increase in 
an avoidable burden placed on the health system. However, in order for asthma to be 
controlled, access to quality care is essential. Disparities in urban areas often produce a 
barrier for individuals to receive properly tailored care for this chronic condition. While 
guidelines exist indicating ways to manage asthma, it is vital that the method used is 
appropriate for the population which is being served.14 
 
The goal of this paper is to show the existence of factors other than environmental 
pollutants, such as socioeconomic status, level of education, and the strength of doctor-
patient relationships (education of disease), that contribute to the high prevalence of 
asthma in high-risk populations. Through completion of this analysis, it is hoped that 
medical treatment and proposed interventions for asthma prevention and reduction can be 
redesigned to account for all influencing factors. 
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PUBLISHED STUDIES 
 PubMed, Science Direct, and Google Scholar were used to search for articles 
pertaining to asthma, its maintenance, treatments and interventions, and burden on high-
risk populations within the United States. The applicable articles used in this research 
were summarized and condensed in an effort to provide supporting evidence for future 
improvements in asthma maintenance. 
 
The Global Asthma Physician and Patient (GAPP) Survey 
  The Global Asthma Physician and Patient (GAPP) Survey is a quantitative study 
conducted across 16 countries aimed at evaluating the perceptions of both physicians and 
patients on asthma treatment and management, education pertaining to symptoms of an 
asthmatic episode, and lastly, the side effects and consequences of medication 
nonadherance.10 In the US 208 adults over the age of 18 with a physician-diagnosed case 
of asthma and 224 physicians who treat 3 or more patients with asthma per week were 
recruited into the study.10 Data was collected using a self-administered online 
questionnaire formatted with close-ended questions regarding patient and physician 
perceptions of the patient’s general asthma education, the frequency of discussion 
regarding short and long-term side effects of asthma medications, and the consequences 
of noncompliance with asthma medications. 
 
 A patient can be concluded to have adequate asthma education if he or she can 
dictate what asthma is, its symptoms, generally what causes an asthmatic episode, their 
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treatment plan, and proper usage of inhaler techniques. In a standard fiduciary doctor-
patient relationship, the burden falls on the physician to provide this knowledge to the 
patient as they are the medially trained entity. However, as shown in Figure 6, physicians 
on average over-estimated the time contributed to asthma education during offices visits 
when compared to patients. 
 
 
Figure 6. Percentage of office visit dedicated to asthma education as 
indicated by physicians and patients.10 
  
Furthermore, similarly, when asked about the knowledge of inhaled corticosteroid 
side effects, physicians indicated a lower percentage of their patients as not knowing the 
associated side effects compared to a higher percentage of patients who self-indicated as 
not being aware (Table 2). 
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Table 2. Patient awareness of inhaled corticoid steroids side effects as indicated by 
physicians and patients10 
 
 
Lastly, significant differences in the responses given by patients and physicians 
were also observed when asked about knowledge of potential health consequences as a 
result of medication noncompliance. As shown in Table 3, physicians indicated more of 
their patients were aware of the dangers associated with noncompliance than patients 
indicated as being aware of. 
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Table 3. Patient awareness of consequences of medication noncompliance as   
indicated by physicians and patients10 
 
The Global Initiative for Asthma Guidelines recommend that physicians and 
patients work as a team to ensure patient knowledge about a disease.10,15 However, 
according to the results published in the GAPP survey, there are significant reported 
differences between the knowledge patients report having and physicians indicate they 
have given. Overall, these results suggest poor patient education in the US. 
Unsurprisingly, these discrepancies were not only observed between patients and 
physicians in the US. Based on the data exhibited in Table 4, significant reported 
differences between patients and physicians occurred globally. 
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Table 4. Comparison of US and Global GAPP survey results10 
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The Effect of Racial and Socioeconomic Factors on Asthma Mortality 
 Marder et al. conducted an observational study in Chicago, Illinois using death 
certificates obtained from the Department of Public Health (DOPH). The parameters for 
inclusion into the study were individuals aged 5 to 34 whose underlying or contributing 
cause of death was related to asthma.16 A total of 205 death certificates were used in the 
study and from which demographic information (i.e. age, sex, race, and socioeconomic 
status) was obtained.16 African-Americans and non-Caucasian Hispanics accounted for 
83% and 17% of death certificates used, respectively. Mortality rates for based on race 
and income were determined for the study population and then compared to that of 
Caucasian subjects in the similar geographical location and age range. Data pertaining to 
asthma mortality rates of Caucasian residents in Chicago were obtained from an initial 
study conducted by Weiss et al.16,17 When asthma mortality rates were compared between 
African-Americans and Caucasians, it was found that across all age groups African-
Americans had at least five times the mortality rate of Caucasians (Figure 7). 
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Figure 7. Asthma mortality rates by race and age group16 
 
 
When taking a closer look at the areas in which the deaths occurred, it was found 
that asthma deaths disproportionately affected predominately black low socioeconomic 
neighborhoods on the south and west side of the city.16 Asthma mortality rates for these 
areas were found to be higher than that of the general African-American population in 
Chicago. 
 
Furthermore, this study also assessed asthma mortality rates by race and average 
household income. A significant (p = 0.0001) inverse relationship was observed between 
the mortality rate and average household income when Caucasians and African-
Americans were combined and assessed across all SES groups.16 However, when 
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African-Americans were examined separately, the inverse relationship, although present, 
was no longer significant (Figure 8). 
 
 
Figure 8. Asthma Mortality rates by race and SES16 
 
Insurance and Quality of Care for Children with Acute Asthma 
 
 Ferris et. al. combined prospective data from 3 inception cohort studies from 36 
emergency departments (ED) across 17 states on patients who had a physician diagnosis 
of asthma between the ages of 2 and 17 that presented to the ED with acute asthmatic 
symptoms.18 Demographic information including asthma history, causes of exacerbation 
of asthma and types of insurance were collected on 1,184 participants who were enrolled 
into the study. Based on the chart review, four categories of insurance type were 
constructed and included managed care (prepaid plan, PPOs), indemnity (fee-for-service), 
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Medicaid, and uninsured.18 The goal of this study was to assess whether a child’s 
insurance status effects the quality and outcomes of care for their acute asthma.18 Pre-ED 
and ED visits were used to indicate quality of care and measured through use of a 
questionnaire that inquired about 1) visiting a primary care physician prior to coming to 
the ED and 2) if the ED was site in which care and treatment for asthma was conducted, 
3) use of an inhaled steroid, and 4) having a written at home asthma plan. Based on 
responses from participants and available hospital records, it was found that individuals 
with managed care and indemnity were more likely to visit their PCP the week prior to 
visiting an ED indicating access to better quality of care.18  
 
Comparatively, children with Medicaid and those who were not insured ranked 
lower on the quality measurement performance scale than those with a form of privatized 
insurance.18 Across the board uninsured children with asthma ranked the lowest in each 
quality measure. Furthermore, it was also found that Medicaid and uninsured participants 
were more likely visit an ED to seek care for acute asthma symptoms and less likely to 
have a designated PCP, when compared with managed care and indemnity participants.18 
As exhibited in table 5, individuals who had Medicaid or were uninsured on average had 
worst measures of quality care than those with privatized insurance. 
 
 
  
 
 
 
 
 
 
      Table 5. Quality measurements of care according to insurance status18 
23 
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Implications for Improving Medication Adherence 
 Horne et. al conducted an analysis on understanding the factors that influence 
patients to be non-adherent with asthma regimens. To adequately address noncompliance, 
it is essential to understand its underlying motives. Noncompliance can arguably be 
divided into two subcategories, intentional and unintentional non-adherance.19 Horne et. 
al indicates intentional non-adherence occurs when a patient decides to take medications 
other than how prescribed, or discontinue use completely. This includes altering the 
dosage or frequency of use.19 Unintentional non-adherence, on the other hand, occurs 
when external barriers prevent a patient from following the indicated regimen; including 
poor recall, comprehension, and physical inability.19 Although, each type is clearly 
defined, noncompliant patients often have a mixture of influencer types. 
  
Horne et. al carried out a study analyzing the perceived concerns and necessity of 
current asthma treatment among individuals with high and low adherence. As shown in 
Figure 9, the study found that individuals with low adherence to their asthma treatment 
had lower perceived necessity but higher concerns about their medication regimen than 
those with high adherence.19 When the concerns of all study participants were further 
investigated, it was found that many things influenced their behavior of poor adherence; 
including meager patient education surrounding medication side effects and long-term 
effects (Figure 10). Horn et. al concluded that it is important to evaluate knowledge, 
motivation, and patient factors associated with adherence.19 
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Figure 9. Perceived concerns and necessity of current asthma treatment among 
individuals with high and low adherence19 
 
 
 
Figure 10. Profile of concerns regarding current asthma treatment19 
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Criterion for Successful Asthma Interventions 
 Clark et. al set out to compare and analyze various interventions targeted at 
reducing asthma prevalence and morbidity in the US. Various interventions assessed 
included those implemented in asthmatic children’s homes targeted at dust mite 
reduction, within communities targeted at improving quality of care received, and out-
reach programs geared towards improving patient asthma education.20 Through 
observational and statistical analysis of these interventions, a model of influence of 
disease control was constructed, as well as, criteria for the successful implementation of 
interventions were revealed. 
 
 Clark et. al determined that in order for asthma to be effectively controlled, it 
requires attention and involvement from a wide range of stakeholders.20 As depicted in 
Figure 11, the patient, family, clinicians, work/school support, community, environment, 
and policy all contribute to disease maintenance in varying degrees; the closer the rings 
are to the center, indicates a greater impact.20 Family has the biggest impact on disease 
control, especially if the afflicted individual is a child, since extensive physical and 
emotional support is required. Next, are clinicians, whom are expected to provide 
medical services and guidance for the patient and family to control the disease.20 Moving 
towards the outer rings of the diagram, it can be seen that work/school, communities, 
environmental controls, and even legislation in the form of policy can have an impact on 
the maintenance of asthma. 
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Figure 11. Factors that influence Disease management.20 
 
 
 Many of the interventions explored in this study had areas of success pertaining to 
asthma control in their respective areas; thus, based on their achievements, the goals and 
characteristics of these organizations were compared to determine if common features 
were evident amongst them. It was found that successful interventions recognized 
multiple factors that influence asthma and its control, carefully assessed individual risk 
factors and needs towards achieving asthma control, specifically tailoring program 
elements to the individual, basing interventions on realistic principles, and considering 
both the physical and social environment.20 
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DISCUSSION 
 
 Often times in medicine when a treatment is developed, it is designed to be 
effective for the majority of the population. Usually this feat poses little issue for 
communicable diseases, as there is commonly a single source for illness. For non-
communicable diseases like asthma, the cause and effect analysis necessary for the 
development of treatments is cumbersome and multivariable. The source of origin for 
asthma is unknown however, through vigorous research effective treatments such as 
Beta-agonists and combination therapies. Unlike therapies designed for communicable 
diseases, these treatments do not “cure” the disease; rather they treat the symptoms 
associated with asthmatic episodes. These vital medicines have led to the general 
decrease in asthma associated mortality rates. However, when studies such as those 
conducted by Blaiss et. al, Marder et. al, Horne et. al and Ferris et al take a closer look at 
the distribution of asthma amongst US citizens, their results showed increased asthma 
rates within subsets of the population. 
 
Chronic disorders typically place substantial burden on health care systems. As 
indicated by Lozano et. al, individuals with asthma tend to rely on the health system more 
than those without asthma and incur at least twice as much health expenditure as a result. 
Thus, knowing what causes high risk population to have uncontrolled asthma 
interventions could be improved. A managed chronic disease would not only reduce the 
burden on the health system but also on low socioeconomic communities suffering from 
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asthma. A key way to manage chronic diseases is through medication compliance. As 
indicated by Horne et. al, medication noncompliance cost the US health system 
approximately $100 billion a year from expired and unused dispensed medicines;19 thus, 
understanding the causes of non-adherence can reduce the financial burden and mortality 
rates of chronic ailments.  
 
Blaiss et. al study results highlights an important issue within the US health 
system among patients and physicians. It emphasizes the perspectival difference between 
physicians and their asthmatic patients, where physicians believe their patients are more 
knowledgeable about their diagnosis than what is reported by patients. The lack of 
continuity between physicians and patients suggests poor patient education in healthcare 
settings. Furthermore, Horne et. al indicated in his study that concerns regarding asthma 
treatment for non-adherent asthmatics mainly stems from a lack of basic information, the 
likelihood of becoming dependent, and potential side effects of their asthma medication. 
Therefore, improving patient education by tailoring it to address the specific concerns of 
patients could improve asthma maintenance in high-risk populations. 
 
In alignment with other countries in both the developed and developing worlds, 
the poor and disenfranchised bear the brunt of asthma disparities within the United States. 
As found by Marder et. al, when comparing African-Americans and Caucasians in 
Chicago African-Americans were found to have a substantially higher rate of asthma 
mortality than Caucasians. Furthermore, when socioeconomic status was also evaluated, 
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poor African-Americans were found to have the highest rates of mortality than wealthier 
individuals of both black and white decent. These results indicated that although 
urbanized areas often have higher asthma prevalence, specific ethnic populations are 
likely to be more impacted than others, as well as specific socioeconomic groups.  
 
As noted by Ferris et. al a difference in quality of care received for asthma 
treatment was observed for individuals who had different insurers. Specifically, it was 
found that individuals who had Medicaid or were uninsured on average had worse 
measures of quality care than those with privatized insurance. Typically, individuals of 
low socioeconomic status are more likely to rely on government programs, like Medicaid, 
for additional assistance. Therefore, it can also be concluded that in addition to ethnicity 
and SES status, types of insurance can also impact asthma management. Lastly, Blaiss et. 
al also indicated patient education as an additional influence on asthma management, by 
showing the disparity in responses given by patients and physicians regarding their 
knowledge about asthma. Despite the responsibility placed on physicians to provide 
education and treatment of a disease, many patients reported not knowing the side effects 
of asthma medications or the consequences of non-adherence to treatment. Thus, when 
asthma is poorly managed, it will cause preventable increases in DALYs, premature 
deaths, and health care expenditure for both the individual and the system. 
 
In addition to research conducted on environmental pathogens, disparities in 
socioeconomic status, patient education, and medical insurance can be taken into account 
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when designing effective asthma interventions, especially within high-risk areas. As 
indicated by Clark et. al successful interventions usually recognize multiple factors that 
influence asthma and its control, carefully assess individual risk factors and needs 
towards achieving asthma control, and specifically tailor program elements to the 
individual. In closing, since many interventions are geared towards the reduction of 
environmental pathogens associated with the exacerbation of asthma, it is hoped that with 
the evidence and recommendations provided within this analysis, interventions will be 
reformed in the future. 
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CONCLUSION 
 
 As shown in this analysis, asthma maintenance is influenced by many factors 
including those not generally acknowledged in many interventions and treatment 
approaches. As shown, there is a specific demographic population in which asthma 
prevalence and mortality rate is unusually high. Furthermore, the association of this high-
risk population with lack of patient education, low socioeconomic status, and Medicaid, 
indicates the influence of these factors. By improving current asthma interventions and 
remodeling them to take a broader stance by also acknowledging the presence of these 
disparities, asthma will likely be better controlled for all individuals in the US. 
Ultimately, if success is achieved with the newly innovated interventions, they may be 
used in other countries who are experiencing comparable difficulties with asthma 
maintenance. 
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